$5.46
+0.01
(+0.18%)▲
Insights on Amneal Pharmaceuticals Inc.
Revenue is down for the last 2 quarters, 620.04M → 616.98M (in $), with an average decrease of 0.5% per quarter
Netprofit is down for the last 3 quarters, 11.91M → -98.64M (in $), with an average decrease of 568.8% per quarter
In the last 3 years, Neurocrine Biosciences Inc. has given 37.7% return, outperforming this stock by 45.2%
1.65%
Downside
Day's Volatility :2.54%
Upside
0.91%
71.06%
Downside
52 Weeks Volatility :75.54%
Upside
15.48%
Period | Amneal Pharmaceuticals Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 4.01% | -0.5% | 0.0% |
6 Months | 46.51% | 5.9% | 0.0% |
1 Year | 230.3% | 3.1% | -1.9% |
3 Years | -4.05% | 14.2% | -21.8% |
Market Capitalization | 1.7B |
Book Value | $0.07 |
Earnings Per Share (EPS) | -0.48 |
Wall Street Target Price | 7.25 |
Profit Margin | -3.51% |
Operating Margin TTM | 13.19% |
Return On Assets TTM | 4.67% |
Return On Equity TTM | -36.06% |
Revenue TTM | 2.4B |
Revenue Per Share TTM | 13.59 |
Quarterly Revenue Growth YOY | 1.2% |
Gross Profit TTM | 791.5M |
EBITDA | 500.8M |
Diluted Eps TTM | -0.48 |
Quarterly Earnings Growth YOY | -0.95 |
EPS Estimate Current Year | 0.58 |
EPS Estimate Next Year | 0.66 |
EPS Estimate Current Quarter | 0.09 |
EPS Estimate Next Quarter | 0.11 |
What analysts predicted
Upside of 32.78%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.7B | ↑ 60.88% |
Net Income | -169.7M | ↓ 201.24% |
Net Profit Margin | -10.21% | ↓ 26.43% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.6B | ↓ 2.2% |
Net Income | -603.6M | ↑ 255.62% |
Net Profit Margin | -37.11% | ↓ 26.9% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 2.0B | ↑ 22.51% |
Net Income | 68.6M | ↓ 111.36% |
Net Profit Margin | 3.44% | ↑ 40.55% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 2.1B | ↑ 5.08% |
Net Income | 20.2M | ↓ 70.59% |
Net Profit Margin | 0.96% | ↓ 2.48% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.2B | ↑ 5.67% |
Net Income | -254.8M | ↓ 1363.21% |
Net Profit Margin | -11.52% | ↓ 12.48% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.4B | ↑ 8.2% |
Net Income | -84.0M | ↓ 67.03% |
Net Profit Margin | -3.51% | ↑ 8.01% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 545.6M | ↓ 2.47% |
Net Income | -2.4M | ↓ 99.0% |
Net Profit Margin | -0.44% | ↑ 42.48% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 609.8M | ↑ 11.77% |
Net Income | -5.9M | ↑ 145.1% |
Net Profit Margin | -0.96% | ↓ 0.52% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 557.5M | ↓ 8.56% |
Net Income | -10.1M | ↑ 72.31% |
Net Profit Margin | -1.81% | ↓ 0.85% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 599.0M | ↑ 7.44% |
Net Income | 11.9M | ↓ 218.06% |
Net Profit Margin | 1.99% | ↑ 3.8% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 620.0M | ↑ 3.5% |
Net Income | 9.7M | ↓ 18.75% |
Net Profit Margin | 1.56% | ↓ 0.43% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 617.0M | ↓ 0.49% |
Net Income | -98.6M | ↓ 1118.89% |
Net Profit Margin | -15.99% | ↓ 17.55% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 4.4B | ↑ 224.37% |
Total Liabilities | 3.5B | ↑ 101.25% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 3.7B | ↓ 15.78% |
Total Liabilities | 3.3B | ↓ 3.97% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 4.0B | ↑ 9.28% |
Total Liabilities | 3.7B | ↑ 10.3% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 3.9B | ↓ 1.66% |
Total Liabilities | 3.6B | ↓ 2.41% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 3.8B | ↓ 3.56% |
Total Liabilities | 3.6B | ↑ 0.5% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 3.5B | ↓ 8.6% |
Total Liabilities | 3.5B | ↓ 3.84% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.9B | ↓ 4.14% |
Total Liabilities | 3.9B | ↑ 0.03% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.8B | ↓ 1.93% |
Total Liabilities | 3.6B | ↓ 6.78% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.6B | ↓ 4.55% |
Total Liabilities | 3.5B | ↓ 3.51% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.7B | ↑ 2.05% |
Total Liabilities | 3.5B | ↑ 1.55% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.7B | ↓ 0.37% |
Total Liabilities | 3.5B | ↓ 0.63% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.5B | ↓ 5.82% |
Total Liabilities | 3.5B | ↓ 1.23% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 250.2M | ↑ 6.85% |
Investing Cash Flow | -396.4M | ↑ 302.19% |
Financing Cash Flow | 287.7M | ↓ 402.77% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.7M | ↓ 99.32% |
Investing Cash Flow | -19.6M | ↓ 95.06% |
Financing Cash Flow | -45.8M | ↓ 115.93% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 379.0M | ↑ 22128.8% |
Investing Cash Flow | -317.5M | ↑ 1521.79% |
Financing Cash Flow | 131.8M | ↓ 387.58% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 241.8M | ↓ 36.2% |
Investing Cash Flow | -194.2M | ↓ 38.85% |
Financing Cash Flow | -138.1M | ↓ 204.79% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 65.1M | ↓ 73.08% |
Investing Cash Flow | -174.3M | ↓ 10.23% |
Financing Cash Flow | -106.6M | ↓ 22.81% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 93.6M | ↓ 174.55% |
Investing Cash Flow | -49.3M | ↑ 206.11% |
Financing Cash Flow | -46.1M | ↓ 298.43% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -23.3M | ↓ 124.89% |
Investing Cash Flow | -11.5M | ↓ 76.76% |
Financing Cash Flow | -22.2M | ↓ 51.95% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 139.7M | ↓ 699.83% |
Investing Cash Flow | -11.7M | ↑ 2.36% |
Financing Cash Flow | -12.9M | ↓ 41.81% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -11.3M | ↓ 108.12% |
Investing Cash Flow | -12.3M | ↑ 4.66% |
Financing Cash Flow | -12.3M | ↓ 4.99% |
Sell
Neutral
Buy
Amneal Pharmaceuticals Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Amneal Pharmaceuticals Inc. | -7.78% | 46.51% | 230.3% | -4.05% | -56.43% |
Neurocrine Biosciences Inc. | -4.63% | 16.46% | 27.73% | 40.21% | 63.9% |
Haleon Plc Spon Ads | -0.25% | -2.88% | -6.68% | 9.31% | 9.31% |
Zoetis Inc. | -10.35% | -12.19% | -12.37% | -8.97% | 56.17% |
Viatris Inc. | -5.44% | 17.92% | 12.21% | -16.08% | -31.95% |
Catalent, Inc. | -0.32% | 22.03% | 22.78% | -48.65% | 30.48% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Amneal Pharmaceuticals Inc. | 89.83 | NA | NA | 0.58 | -0.36 | 0.05 | NA | 0.07 |
Neurocrine Biosciences Inc. | 54.74 | 54.74 | 0.44 | 4.69 | 0.13 | 0.09 | NA | 22.61 |
Haleon Plc Spon Ads | 28.79 | 28.79 | 1.69 | 0.45 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 29.48 | 29.48 | 2.58 | 5.8 | 0.5 | 0.13 | 0.01 | 10.9 |
Viatris Inc. | 226.4 | 226.4 | NA | 2.78 | 0.0 | 0.03 | 0.04 | 17.05 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.48 | -0.3 | -0.01 | NA | 20.41 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Amneal Pharmaceuticals Inc. | Buy | $1.7B | -56.43% | 89.83 | -3.51% |
Neurocrine Biosciences Inc. | Buy | $13.5B | 63.9% | 54.74 | 13.23% |
Haleon Plc Spon Ads | Buy | $37.0B | 9.31% | 28.79 | 9.28% |
Zoetis Inc. | Buy | $68.5B | 56.17% | 29.48 | 27.43% |
Viatris Inc. | Hold | $13.4B | -31.95% | 226.4 | 0.35% |
Catalent, Inc. | Hold | $10.1B | 30.48% | 211.02 | -31.77% |
Fosun International Ltd
Vanguard Group Inc
TPG GP A, LLC
BlackRock Inc
Rubric Capital Management LP
Nantahala Capital Management, LLC
an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.
Organization | Amneal Pharmaceuticals Inc. |
Employees | 7850 |
CEO | Mr. Chirag K. Patel |
Industry | Health Technology |